University of the Philippines Manila
The Health Sciences Center
BIDS & AWARDS COMMITTEE IV (BAC IV)

Proj. Ref. No. **BAC1-2022-08-0051-C**
End-User **Property and Supply Division, PGH** **Opening of Bids: 16 September 2022**
Project **Supply and Delivery of Various Drugs and Medicines - IV Fluids, Anaesthetic/Respiratory Inhalants, Liquid/Suspension Preparation, External/Dermatological, Otic/Ophthalmic Preparation, Others**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
			IV FLUIDS			
107	21,603	piece	Sterile water for injection 100mL bottle/bag (no preservative)	44.36		
			ANAESTHETIC/RESPIRATORY INHALANTS			
108	**420**	piece	Glycopyrronium (as bromide) + Indacaterol (as maleate) Inhalation: 50mcg/110mcg inhalation powder in hard capsules (30's/bx)	54.60		
			LIQUID/SUSPENSION PREPARATION			
109	8640	piece	Sevelamer carbonate 800 mg powder for suspension sachet/packet	36.36		
			EXTERNAL/DERMATOLOGICAL			
110	50	piece	Clobetasol propionate 0.05%, 5 g tube Cream or Ointment	70.85		
			OTIC/OPHTHALMIC PREPARATION			
111	1009	piece	Prednisolone acetate eye drops suspension 1%, 5mL bottle	102.90		
			OTHERS			
112	13512	piece	Povidone Iodine Solution: 10%, 120mL bottle	240.45		
113	9,132	piece	Povidone Iodine Surgical Skin Cleanser: 7.5%, 120 mL bottle	290.85		
TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP7,307,762.68						

Approved by:

Dean CHARLOTTE M. CHIONG, MD, PhD
Chairperson

_____
(Signature over Printed Name of President/Gen. Manager)

_____
(Name & Address of Company)

University of the Philippines Manila
The Health Sciences Center
BIDS & AWARDS COMMITTEE IV (BAC IV)

Proj. Ref. No. **BAC1-2022-08-0051-C**
End-User **Property and Supply Division, PGH** **Opening of Bids: 16 September 2022**
Project **Supply and Delivery of Various Drugs and Medicines - IV Fluids, Anaesthetic/Respiratory Inhalants, Liquid/Suspension Preparation, External/Dermatological, Otic/Ophthalmic Preparation, Others**

TERMS AND CONDITIONS

1. Indicate the **brand and packing of the item/s** offered.

2. The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).

3. Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).

3.1. Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distribu
Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized t tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in ca termination of distributorship agreement.

3.2. Valid Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).

- The name of the respective distributor should appear on the submitted CPR of the drug.

Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application v Document Tracking log for the CPR from the FDA.

3.3. Certificate of Analysis (COA) for the products offered (batch to be delivered if awarded) duly issued by an FDA-accredited laboratory (lo and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bi The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidd In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is prefe and given more weight in the evaluation and awarding process.

3.4. A notarized certificate that it is the innovator drug (if applicable).

3.5. Certificate of Good Manufacturing Process (CGMP).

3.6. Valid License to Operate (LTO).

3.7. A notarized certificate that the offered brand has not been subject to product complaint/product recall for the past three (3) years.

3.8. Certificate of Acceptance from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (for new item/brand offered only).

3.9. A notarized certificate that there are sufficient stocks for the offered item/s for one (1) year.

4. The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Approved by:

4.1. For all tablets and capsules

4.1.1. All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.

4.1.2. Each individual flap in the tablet or capsule blister pack should be labeled with the generic r **Dean VICENTE Y. BELIZARIO, JR., M.D.**

4.1.3. Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on *Chairperson*

4.1.4. Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packi However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expir should appear on each unit.

4.1.5. Inner label must be the same as the outer label.

4.1.6. A complete drug literature/product insert must accompany the product.

5. The following must be complied with specific for **cytotoxic injectable drugs.**

5.1. For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to

Proj. Ref. No. **BAC1-2022-08-0051-C**
End-User **Property and Supply Division, PGH** **Opening of Bids: 16 September 2022**
Project **Supply and Delivery of Various Drugs and Medicines - IV Fluids, Anaesthetic/Respiratory Inhalants, Liquid/Suspension Preparation, External/Dermatological, Otic/Ophthalmic Preparation, Others**

the Pharmacy Department per company under the first Purchase Order.

5.2. Winning bidders for cytotoxic injectable drugs are required to provide at least three (3) spill kits per company under the first Purchase Ord

6. New brands offered shall be subject to further evaluation and shall require the following:

6.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;

6.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

7. For the supply and delivery of awarded drugs and medicines.

7.1. Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confir fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.

7.2. Delivery schedule (whichever is applicable):

7.2.1. within seven (7) calendar days;

7.2.2. as may be called for;

7.2.3. staggered delivery within three (3) months

*** 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months**

Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital

7.3. Deliveries shall have **at least two (2) years expiration date.**

7.4. Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proc with the acceptance or to cancel/return the items.

7.5. Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.

7.6. Stocks delivered **are subject to random sampling for testing** as to quality and conformity to label. Testing fee at supplier's expense.

7.7. Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity t Testing fee at supplier's expense.

7.8. All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a de shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.

7.9. It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first** as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA). Purchase from other source fo shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.

8. Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 91

9. Compliance with RA 9184 and other applicable laws.

Approved by:

Dean CHARLOTTE M. CHIONG, MD, PhD
Chairperson

_____
(Signature over Printed Name of President/Gen. Manager)

_____
(Name & Address of Company)